NewsRx

Search our medical news database

Bradmer Pharmaceuticals, Inc.

Bradmer commences trading on Toronto Stock Exchange

Published in Lab Business Week, May 21st, 2006

Bradmer Pharmaceuticals, Inc., a biotechnology company dedicated to the development and commercialization of cancer therapies, announced that its common shares were approved for listing on the Toronto Stock Exchange (TSX) and will no longer trade on the TSX Venture Exchange.

Trading on the TSX commenced on April 18, 2006, at the market opening under the symbol "BMR."

"We believe the transition to the TSX from the TSX Venture reflects the maturity of Bradmer's lead product candidate Neuradiab. This transition is in keeping with our strategy to advance the corporate progress of the company by broadening the base of potential investors to support our...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook